Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017136350 - AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF

Publication Number WO/2017/136350
Publication Date 10.08.2017
International Application No. PCT/US2017/015856
International Filing Date 31.01.2017
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G01N 33/566 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
CPC
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 2317/41
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
40characterized by post-translational modification
41Glycosylation, sialylation, or fucosylation
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
G01N 33/564
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
564for pre-existing immune complex or autoimmune disease ; , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Applicants
  • NOVELMED THERAPEUTICS, INC. [US]/[US]
Inventors
  • BANSAL, Rekha
Agents
  • SUTKUS, Richard A.
Priority Data
15/012,45701.02.2016US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
(FR) ANTICORPS ANTI-C3B AGLYCOSYLÉS ET LEURS UTILISATIONS
Abstract
(EN)
An aglycosylated humanized anti-C3b (AAC3b) antibody or antigen binding fragment thereof includes a modification at a conserved N-linked site in the CH2 domains of an Fc portion of the antibody or antigen binding fragment thereof.
(FR)
Un anticorps anti-C3b humanisé aglycosylé (AAC3b) ou un fragment de liaison d'antigène de celui-ci comprend une modification au niveau d'un site à liaison N conservé dans les domaines CH2 d’une partie Fc de l'anticorps ou du fragment de liaison d'antigène de celui-ci.
Also published as
Latest bibliographic data on file with the International Bureau